• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

c-Met 过表达与多形性胶质母细胞瘤的不良预后相关：系统评价和荟萃分析。

Overexpression of c-Met is Associated with Poor Prognosis in Glioblastoma Multiforme: A Systematic Review and Meta-Analyses.

机构信息

Department of Radiation Oncology, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

出版信息

Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3075-3080. doi: 10.31557/APJCP.2021.22.10.3075.

DOI:10.31557/APJCP.2021.22.10.3075
PMID:34710981
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8858257/
Abstract

OBJECTIVE

The aim of this study is to evaluate the association of c-Met overexpression with survival of glioblastoma multiforme (GBM) patients.

METHODS

A systematic review with meta-analyses was conducted on related articles from PubMed, EBSCOhost, Scopus, and Cochrane databases with last updated search on October 31, 2020. A total of 7 studies regarding c-Met overexpression and overall survival (OS) and/or progression free survival (PFS) are included in this study.

RESULTS

All studies used immunohistochemistry to examine the expression of c-Met protein. The results showed that the positive rate of c-Met overexpression was detected in approximately 33,9% - 60,5% of GBM patients. c-Met overexpression was related to worse OS (HR: 1,74; 95% CI: 1,482-2,043; Z=6,756; p<0,001) and PFS (HR: 1,66; 95% CI: 1,327-2,066; Z=4,464; p<0,001) in GBM patients. Low heterogeneity of subjects was found in both OS and PFS analyses, I2 values were 7,8% and 0,0%, respectively.

CONCLUSION

In conclusion, c-Met overexpression is significantly related to shorter OS and PFS in GBM patients, so c-Met can be considered as a potential prognostic indicator in GBM.

摘要

目的

本研究旨在评估 c-Met 过表达与胶质母细胞瘤（GBM）患者生存的相关性。

方法

对 2020 年 10 月 31 日之前从 PubMed、EBSCOhost、Scopus 和 Cochrane 数据库中检索到的相关文章进行了系统评价和荟萃分析。共有 7 项关于 c-Met 过表达与总生存期（OS）和/或无进展生存期（PFS）的研究纳入本研究。

结果

所有研究均采用免疫组织化学法检测 c-Met 蛋白的表达。结果表明，GBM 患者中约有 33.9%-60.5%检测到 c-Met 过表达。c-Met 过表达与较差的 OS（HR：1.74；95%CI：1.482-2.043；Z=6.756；p<0.001）和 PFS（HR：1.66；95%CI：1.327-2.066；Z=4.464；p<0.001）相关。OS 和 PFS 分析中，患者的异质性较低，I2 值分别为 7.8%和 0.0%。

结论

总之，c-Met 过表达与 GBM 患者的 OS 和 PFS 显著缩短相关，因此 c-Met 可被视为 GBM 的潜在预后指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b61/8858257/1c453e106bb6/APJCP-22-3075-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b61/8858257/00a2933db3de/APJCP-22-3075-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b61/8858257/97209065b5d8/APJCP-22-3075-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b61/8858257/1c453e106bb6/APJCP-22-3075-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b61/8858257/00a2933db3de/APJCP-22-3075-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b61/8858257/97209065b5d8/APJCP-22-3075-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b61/8858257/1c453e106bb6/APJCP-22-3075-g003.jpg

相似文献

1
Overexpression of c-Met is Associated with Poor Prognosis in Glioblastoma Multiforme: A Systematic Review and Meta-Analyses.c-Met 过表达与多形性胶质母细胞瘤的不良预后相关：系统评价和荟萃分析。
Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3075-3080. doi: 10.31557/APJCP.2021.22.10.3075.
2
c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.c-Met 表达与多形性胶质母细胞瘤患者的复发时间有关。
J Clin Neurosci. 2011 Jan;18(1):119-21. doi: 10.1016/j.jocn.2010.05.010. Epub 2010 Sep 15.
3
The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme.c-Met的免疫组化表达是多形性胶质母细胞瘤患者生存的独立预测指标。
Clin Transl Oncol. 2014 Feb;16(2):173-7. doi: 10.1007/s12094-013-1059-4. Epub 2013 Jun 6.
4
MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-analysis.MGMT 启动子甲基化与胶质母细胞瘤预后：系统评价与荟萃分析。
Arch Med Res. 2013 May;44(4):281-90. doi: 10.1016/j.arcmed.2013.04.004. Epub 2013 Apr 19.
5
Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.多尺度放射组学分析预测胶质母细胞瘤患者的生存情况。
Med Biol Eng Comput. 2018 Dec;56(12):2287-2300. doi: 10.1007/s11517-018-1858-4. Epub 2018 Jun 19.
6
Baseline single institutional retrospective review of body mass index (BMI) as a prognostic indicator in patients with newly diagnosed glioblastoma (GBM).对新诊断的胶质母细胞瘤（GBM）患者的体重指数（BMI）作为预后指标的单机构回顾性基线研究。
J Clin Neurosci. 2024 Sep;127:110754. doi: 10.1016/j.jocn.2024.07.015. Epub 2024 Jul 27.
7
Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome.中性粒细胞与淋巴细胞比值和预后营养指数与其他临床和分子生物标志物在预测多形性胶质母细胞瘤结局中的比较。
PLoS One. 2021 Jun 17;16(6):e0252614. doi: 10.1371/journal.pone.0252614. eCollection 2021.
8
Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis.胶质母细胞瘤中高尔基磷蛋白-3（GOLPH3）的过表达与预后不良相关。
J Neurooncol. 2012 Nov;110(2):195-203. doi: 10.1007/s11060-012-0970-9. Epub 2012 Sep 13.
9
CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.CDC6 在多形性胶质母细胞瘤中上调并作为预后不良的标志。
Clin Transl Oncol. 2021 Mar;23(3):565-571. doi: 10.1007/s12094-020-02449-w. Epub 2020 Jul 13.
10
Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.在一项针对新诊断胶质母细胞瘤患者的回顾性分析中，在确定性放疗和替莫唑胺治疗期间给予地塞米松预后较差。
Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.

引用本文的文献

1
MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature.实体瘤中MET改变的检测平台及其临床意义：文献综述
Ther Adv Med Oncol. 2024 Jan 18;16:17588359231221910. doi: 10.1177/17588359231221910. eCollection 2024.
2
Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?解析胶质母细胞瘤肿瘤微环境：适体靶向递送能否成功用于治疗脑癌？
Cancers (Basel). 2023 Sep 1;15(17):4376. doi: 10.3390/cancers15174376.
3
Anti-c-MET Fab-Grb2-Gab1 Fusion Protein-Mediated Interference of c-MET Signaling Pathway Induces Methuosis in Tumor Cells.

本文引用的文献

1
MET in glioma: signaling pathways and targeted therapies.MET 在脑胶质瘤中的作用：信号通路和靶向治疗。
J Exp Clin Cancer Res. 2019 Jun 20;38(1):270. doi: 10.1186/s13046-019-1269-x.
2
c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.c-Met 表达是 IDH 突变型低级别胶质瘤和 IDH 野生型胶质母细胞瘤预后预测的有用标志物。
World Neurosurg. 2019 Jun;126:e1042-e1049. doi: 10.1016/j.wneu.2019.03.040. Epub 2019 Mar 13.
3
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015.
抗 c-MET Fab-Grb2-Gab1 融合蛋白介导的 c-MET 信号通路干扰诱导肿瘤细胞溶酶体过度生成。
Int J Mol Sci. 2022 Oct 10;23(19):12018. doi: 10.3390/ijms231912018.
CBTRUS统计报告：2011 - 2015年美国原发性脑肿瘤及其他中枢神经系统肿瘤诊断情况
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131.
4
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.c-Met 受体酪氨酸激酶在肿瘤发生中的作用及相关治疗机会。
Mol Cancer. 2018 Feb 19;17(1):45. doi: 10.1186/s12943-018-0796-y.
5
Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.肝细胞生长因子/间质-上皮转化因子通路在胶质母细胞瘤中的作用及治疗靶向
Cancers (Basel). 2017 Jul 11;9(7):87. doi: 10.3390/cancers9070087.
6
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.基于分子的胶质母细胞瘤在替莫唑胺时代的递归分区分析模型：基于 NRG 肿瘤学 RTOG 0525 的相关性分析。
JAMA Oncol. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.
7
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
8
c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.c-Met介导的内皮可塑性驱动胶质母细胞瘤中的异常血管生成和化疗耐药性。
J Clin Invest. 2016 May 2;126(5):1801-14. doi: 10.1172/JCI84876. Epub 2016 Apr 4.
9
Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.低c-Met表达水平对恶性胶质瘤替莫唑胺化疗具有预后价值并可预测其疗效。
Sci Rep. 2016 Feb 16;6:21141. doi: 10.1038/srep21141.
10
C-MET overexpression and amplification in gliomas.胶质瘤中C-MET的过表达与扩增
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14932-8. eCollection 2015.